MiiS (6796) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 晉弘

MiiS (6796) reported revenue of NT$72.7 million for Oct 2026, +6.7% year on year and +7.5% from the previous month. Revenue for Jan–Oct 2026 was NT$596.7 million (+17.2% year on year).

Year-on-year revenue growth: 5 months in a row. →

In Oct 2026, it ranked No. 90 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$48.5 million24/10Nov 2024 NT$50.1 millionDec 2024 NT$116.5 millionJan 2025 NT$37 millionFeb 2025 NT$41.2 million25/02Mar 2025 NT$55.5 millionApr 2025 NT$43.4 millionMay 2025 NT$56.9 millionJun 2025 NT$54 million25/06Jul 2025 NT$48.3 millionAug 2025 NT$49 millionSep 2025 NT$55.7 millionOct 2025 NT$68.1 million25/10Nov 2025 NT$73.1 millionDec 2025 NT$79.2 millionJan 2026 NT$42.6 millionFeb 2026 NT$44.5 million26/02Mar 2026 NT$60.3 millionApr 2026 NT$54 millionMay 2026 NT$52.9 millionJun 2026 NT$54.6 million26/06Jul 2026 NT$86.5 millionAug 2026 NT$61.1 millionSep 2026 NT$67.6 millionOct 2026 NT$72.7 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$72.7 million+6.7%+7.5%
Sep 2026NT$67.6 million+21.3%+10.7%
Aug 2026NT$61.1 million+24.6%-29.4%
Jul 2026NT$86.5 million+79.2%+58.5%
Jun 2026NT$54.6 million+1.0%+3.2%
May 2026NT$52.9 million-7.1%-2.0%
Apr 2026NT$54 million+24.4%-10.6%
Mar 2026NT$60.3 million+8.8%+35.6%
Feb 2026NT$44.5 million+8.1%+4.6%
Jan 2026NT$42.6 million+15.0%-46.3%
Dec 2025NT$79.2 million-32.0%+8.4%
Nov 2025NT$73.1 million+45.7%+7.3%
Oct 2025NT$68.1 million+40.3%+22.1%
Sep 2025NT$55.7 million+63.6%+13.7%
Aug 2025NT$49 million+51.6%+1.5%
Jul 2025NT$48.3 million+28.0%-10.6%
Jun 2025NT$54 million+2.7%-5.1%
May 2025NT$56.9 million+86.6%+31.2%
Apr 2025NT$43.4 million+10.1%-21.8%
Mar 2025NT$55.5 million+34.2%+34.7%
Feb 2025NT$41.2 million+119.6%+11.3%
Jan 2025NT$37 million+0.0%-68.2%
Dec 2024NT$116.5 million+118.7%+132.3%
Nov 2024NT$50.1 million-1.0%+3.3%
Oct 2024NT$48.5 million+5.1%+42.5%

Jan–Oct 2026 cumulative: NT$596.7 million (+17.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: MiiS vs PEC / MiiS vs Lotus Pharm / MiiS vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16